Volunteer Login Study Team Login

Print

Lay Description

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Category

  • Diabetes
  • Minority Studies
IRB Number
20150799HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
18 Years -
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Study Contact


Regulatory Point of Contact
Roy Resendez
(210) 585-9776
roy.resendez@utrgv.edu

Principal Investigator
Ravindranath Duggirala